Member Publications

Effect of Age on Rheumatic Immune-Related Adverse Events: Experience From the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)

Objective Immune checkpoint inhibitors (ICIs) have revolutionized cancer outcomes but are limited by immune-related adverse events (irAEs), including rheumatic irAEs (Rh-irAEs)

Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study

Introduction Immune checkpoint inhibitors-induced inflammatory arthritis (ICI-IA) affects about 5% of ICI recipients

Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study

Objective Another course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse events, including inflammatory arthritis (ICI-IA), but there are limited data regarding safety of ICI rechallenge in this setting

Improving Knowledge Dissemination of Rheumatic Toxicities of Cancer Immunotherapy: A Web-Based Educational Initiative

Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group

The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events

De novo Connective Tissue Disorders as Immune-related Adverse Events

Immune Checkpoint Inhibitor associated Remitting Seronegative Symmetrical Synovitis with Pitting Edema (ICI-RS3PE): Description of a New Entity by CanRIO

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Ann Rheum Dis 2020 Background: Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs)

Adverse Events Associated with Immune Checkpoint Blockade

Cohen Tervaert JW, Ye C, Yacyshyn E

N Engl J Med 2018

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients

Machado MAÁ, de Moura CS, Chan K, Curtis JR, Hudson M, Abrahamowicz M, Jamal R, Pilote L, Bernatsky S

Sci Rep 2020

Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort

Roberts J, Ennis D, Hudson M, Ye C, Saltman A, Himmel M, Rottapel R, Pope J, Hoa S, Tisseverasinghe A, Fifi-Mah A, Maltez N, Jamal S

Autoimmun Rev 2020

Moving towards personalized treatments of immune-related adverse events

Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, Miller WH Jr, Calabrese L

Nat Rev Clin Oncol 2020

Immune Checkpoint Inhibitors in Cancer Immunotherapy

CMAJ 2020 Immune checkpoint inhibitors (ICI's) are increasingly used in cancer immunotherapy, and have shown unprecedented survival benefit in a number of malignancies with historically poor prognoses and limited therapeutic options

Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy

Esfahani K, Hudson M, Batist G

N Engl J Med 2020

Checking in with immune checkpoint inhibitors: Results of a needs assessment survey of Canadian rheumatologists

Maltez N, Abdullah A, Fifi-Mah A, Hudson M, Jamal S

J Cancer Sci Therap 2019

Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist

Jamal S, Hudson M, Fifi-Mah A, Ye C

J Rheum 2019

Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis

Roberts J, Smylie M, Walker J, Basappa NS, Chu Q, Kolinsky M, Lyddell C, Ye C

Clin Rheumatol 2019

Adverse events associated with immune checkpoint inhibitor treatment for cancer

Esfahani K, Meti N, Miller WH Jr, Hudson M

CMAJ 2019

Rheumatic Immune-related Adverse Events Associated with Immune Checkpoint Inhibitors for Cancer: Coming soon to a clinic near you.

Ye C, Jamal S, Hudson M

CRAJ 2018